Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is trading at $249.59, about ₹23,966 at today's USD/INR rate, as of 24 Sep 2026, 4:00 PM ET, up 1.25% today. Indian residents can buy Alnylam Pharmaceuticals from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$245.52
Today's high
$251.75
52 week low
$197.81
52 week high
$495.55
ALNY opened at $246.90, closed previously at $246.51, and has traded between $197.81 and $495.55 over the past 52 weeks.
About
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
Key statistics
Avg. volume
1.63M
Market cap
$33.40B
P/E Ratio
40.92
Price-to-sales ratio
6.95
Enterprise value
$32.96B
Free cash flow yield
1.62%
Debt-to-equity ratio
0.94
Return on equity
93.61%
ROIC
24.43%
Beta
0.30
Dividend yield
0.00%
Last dividend
$0.00
Financial overview
Revenue
$3.71B
Earnings per share
$2.39
Free cash flow
$465.38M
Net profit margin
16.82%
Gross margin
79.72%
EBITDA
$631.44M
Revenue growth
65.19%
Similar securities
This is not an investment recommendation
How to buy Alnylam Pharmaceuticals from India
Indian residents can buy Alnylam Pharmaceuticals shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.
Search for Alnylam Pharmaceuticals and place an order
Find Alnylam Pharmaceuticals by name or by its ticker, ALNY, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Alnylam Pharmaceuticals trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Alnylam Pharmaceuticals position in USD and INR. Alnylam Pharmaceuticals pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Alnylam Pharmaceuticals from India
Trading and taxes when buying Alnylam Pharmaceuticals from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneAlnylam Pharmaceuticals does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- US estate tax
- May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator
Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
FAQs
Can Indian residents buy Alnylam Pharmaceuticals stock?
Yes. Alnylam Pharmaceuticals (ALNY) has been listed on NASDAQ since 2004, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
How much does one Alnylam Pharmaceuticals share cost in rupees?
One Alnylam Pharmaceuticals share is $249.59 — about ₹23,966 at a USD/INR rate of 96.02 on 24 Sep 2026. Both the Alnylam Pharmaceuticals price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Alnylam Pharmaceuticals from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
Can I buy Alnylam Pharmaceuticals with less than the price of one share?
Yes. A whole Alnylam Pharmaceuticals share is $249.59, but there is no minimum trade size: you enter a rupee or dollar amount and receive the matching fraction.
How are gains on Alnylam Pharmaceuticals shares taxed in India?
The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Alnylam Pharmaceuticals price. Paasa issues a capital-gains statement for your return.
Does Alnylam Pharmaceuticals pay a dividend?
No. Alnylam Pharmaceuticals does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Alnylam Pharmaceuticals from India?
NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.
Is there estate or inheritance tax on Alnylam Pharmaceuticals shares held from India?
US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.
Do I have to declare Alnylam Pharmaceuticals shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Alnylam Pharmaceuticals holding, its cost and its closing value.
How do I sell Alnylam Pharmaceuticals and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.